Výsledky vyhledávání - "HUNTER GILLIES"

Akademický článek

IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension

Autor: Hunter Gillies, Murali M. Chakinala, Benjamin T. Dake, Jeremy P. Feldman, Marius M. Hoeper, Marc Humbert, Zhi‐Cheng Jing, Jonathan Langley, Vallerie V. McLaughlin, Ralph W. Niven, Stephan Rosenkranz, Xiaosha Zhang, Nicholas S. Hill

Publikováno v: Pulmonary Circulation, Vol 14, Iss 1, Pp n/a-n/a (2024)

Abstract AV‐101 (imatinib) powder for inhalation, an investigational dry powder inhaled formulation of imatinib designed to target the underlying pathobiology of pulmonary arterial hypertension, was generally well tolerated in healthy adults in a p

Externí odkaz: https://doaj.org/article/6cca6181d66a4a5aadc281acfa6b68ed

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study

Autor: Hunter Gillies, Ralph Niven, Benjamin T. Dake, Murali M. Chakinala, Jeremy P. Feldman, Nicholas S. Hill, Marius M. Hoeper, Marc Humbert, Vallerie V. McLaughlin, Martin Kankam

Publikováno v: ERJ Open Research, Vol 9, Iss 2 (2023)

Background Oral imatinib has been shown to be effective, but poorly tolerated, in patients with advanced pulmonary arterial hypertension (PAH). To maintain efficacy while improving tolerability, AV-101, a dry powder inhaled formulation of imatinib, w

Externí odkaz: https://doaj.org/article/6e8ff00f40604cb1bb338a1660e59c87

Zobrazit plný text záznamu

Akademický článek

Acute Corticotropin-Releasing Factor Receptor Type 2 Agonism Results in Sustained Symptom Improvement in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Autor: Gerard Pereira, Hunter Gillies, Sanjay Chanda, Michael Corbett, Suzanne D. Vernon, Tina Milani, Lucinda Bateman

Publikováno v: Frontiers in Systems Neuroscience, Vol 15 (2021)

BackgroundMyalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex multi-symptom disease with widespread evidence of disrupted systems. The authors hypothesize that it is caused by the upregulation of the corticotropin-releasing facto

Externí odkaz: https://doaj.org/article/3a478a96971d4a8a8a157a4ebc58905c

Zobrazit plný text záznamu

Akademický článek

Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.

Autor: Eve-Irene Lepist, Hunter Gillies, William Smith, Jia Hao, Cassandra Hubert, Robert L St Claire, Kenneth R Brouwer, Adrian S Ray

Publikováno v: PLoS ONE, Vol 9, Iss 1, p e87548 (2014)

Inhibition of the transporter-mediated hepatobiliary elimination of bile salts is a putative mechanism for liver toxicity observed with some endothelin receptor antagonists (ERAs).Sandwich-cultured human hepatocytes were used to study the hepatobilia

Externí odkaz: https://doaj.org/article/c42eeeca463f467d81ac31d4e10c3353

Zobrazit plný text záznamu

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial

Autor: JG Coghlan, Joan Albert Barberà, Vallerie V. McLaughlin, Marius M. Hoeper, Andrew J. Peacock, Julia Harris, Nazzareno Galiè, Hunter Gillies, Ambition investigators, Lewis J. Rubin, Gérald Simonneau, Jonathan Langley, Jean-Luc Vachiery, Masataka Kuwana, Karen L. Miller, Christiana Blair, Hossein Ardeschir Ghofrani, Adaani E. Frost

Publikováno v: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 76 (7
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname

Background: Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response compared with idiopathic PAH in most trials. Thus, there is uncertainty regar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::152584aab046b45c6db6271128adf69d
http://europepmc.org/articles/PMC5530350

Zobrazit plný text záznamu

A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis

Autor: Lisa Lancaster, Peter Fernandes, Parag Shah, Ganesh Raghu, Hunter Gillies, Bo Kim, J.E. Loyd, Kevin R. Flaherty, Roger A. Alvarez, Jeffrey J. Swigris, Neil A. Ettinger, Steven D. Nathan, Marilyn K. Glassberg

Publikováno v: Chest. 158(2)

Background The interstitial lung diseases include a variety of disorders, many of which are characterized by fibrotic changes (fILD). Of the fILDs, Idiopathic pulmonary fibrosis is the most common. Pulmonary hypertension (PH) frequently complicates f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a50b1c8c2f0939cd3537aec7b694a5
https://pubmed.ncbi.nlm.nih.gov/32092321

Zobrazit plný text záznamu

Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial

Autor: Aryeh Fischer, James Tislow, Christopher P. Denton, Hunter Gillies, Marco Matucci-Cerinic, Steven D. Nathan, Christiana Blair

Publikováno v: Respiratory Medicine. 117:254-263

Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right ventricular failure and early mortality and is an important complication in patients with connective tissue disease (CTD). Previously, the endothelin A selective r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d40fa34383381d44bba5596606d9be9
https://doi.org/10.1016/j.rmed.2016.06.018

Zobrazit plný text záznamu

Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials

Autor: Kelly Chin, Karen L. Miller, Hunter Gillies, Fernando Torres, Sonja Bartolome, Christiana Blair

Publikováno v: International Journal of Clinical Practice. 68:568-577

Summary Background Recent clinical trials in pulmonary arterial hypertension have included World Health Organization functional classes I and II patients. However, the impact of baseline functional class and other measures of severity on outcomes has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47ead3846212d7e205e2142dd44e6d3a
https://doi.org/10.1111/ijcp.12331

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání